Siga Technologies, Inc. Announces Resignation of Eric A. Rose from Employment with the Company
October 19, 2018 at 01:55 am IST
Share
On October 13, 2018, SIGA Technologies, Inc. entered into a consulting agreement and release (the Rose Consulting Agreement) with Dr. Eric A. Rose. The Rose Consulting Agreement provides that Dr. Rose shall continue to serve as Chairman of the Board of the Company, and will resign from employment with the Company and transition to serve as a consultant to the Company, effective October 13, 2018. Under the Rose Consulting Agreement, Dr. Rose will provide consulting services to the Company for two years, and be compensated for such services at an annual rate of $200,000. Dr. Rose's consulting services will include assisting the Company on expanded indications for TPOXX and other business development opportunities as requested by the Company.
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
SIGA TECHNOLOGIES, INC. 
